Harmony Biosciences Holdings, Inc. filings document a commercial-stage pharmaceutical issuer focused on rare neurological diseases and its WAKIX-centered operating results. Form 8-K reports furnish quarterly and annual financial results, preliminary net product revenue, revenue guidance, investor presentations, and clinical-program updates.
Governance filings include definitive proxy materials for annual meeting matters, board elections, executive compensation, and shareholder voting procedures. Material-event reports also record executive appointments, separations, compensatory arrangements, board changes, Regulation FD disclosures, and exhibit-based updates related to the company’s business and pipeline.
Harmony Biosciences Holdings, Inc. reported record Q2 2026 results, with net product revenue of $261.3 million for WAKIX, representing 30% year-over-year growth and supporting reiterated 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.
Average treated patients were about 8,950, an increase of 450. Cost of product sold was $63.2 million, or 24.2% of net product revenue, primarily reflecting new royalties related to the Novitium license agreement. Net income was $75.4 million, or $1.28 per diluted share, compared with $39.8 million, or $0.68, in Q2 2025. As of June 30, 2026, cash, cash equivalents and investments totaled $962.5 million, and stockholders’ equity was $999.2 million versus $870.2 million at year-end 2025.
The company also highlighted pipeline and regulatory progress. Phase 1 single ascending dose data for orexin-2 agonist BP-205 showed favorable pharmacokinetic and safety/tolerability profiles, with additional Phase 1 and Phase 2 studies planned through 2027. The NDA for Pitolisant GR was accepted with a target PDUFA date of April 1, 2027, while Pitolisant HD is expected to deliver Phase 3 topline data in 2027 and has a target PDUFA date in 2028.
Vanguard Portfolio Management filed a beneficial ownership report on Harmony Biosciences Holdings Inc common stock. Vanguard reports beneficial ownership of 2,943,383 shares, representing 5.08% of the outstanding common stock. Vanguard has sole voting power over 62,894 shares and sole dispositive power over 2,943,383 shares, with no shared voting or dispositive power. The position includes securities held by specified Vanguard affiliates and funds over which they exercise voting and/or dispositive power, and no other individual person’s interest exceeds 5% of the class.
BlackRock, Inc. reports beneficial ownership of 6,525,663 shares of Harmony Biosciences Holdings, Inc. common stock, representing 11.3% of the class. BlackRock has sole voting power over 6,445,523 shares and sole dispositive power over 6,525,663 shares, with no shared voting or dispositive power.
The shares are held across certain BlackRock business units, and various underlying persons have rights to dividends or sale proceeds, but no single such person holds more than five percent of Harmony Biosciences’ outstanding common shares.
Harmony Biosciences Holdings, Inc. reports that officer Stephen M. Mollichella, whose title is listed as "INT PRINCIAL FINANCIAL OFFICER", beneficially holds stock options over 12,172, 8,500, 7,050 and 20,750 shares of common stock with exercise prices from 30.6900 to 38.0100, expiring between 2031 and 2036. He also holds restricted stock units over 2,625, 3,488 and 5,900 shares that vest in annual installments beginning in 2027, subject to continued service, and 2,506 shares of common stock directly.
Harmony Biosciences reported preliminary, unaudited Q2 2026 net product revenue for WAKIX of approximately $261 million, a record quarterly level, with 30% year-over-year and 21% sequential growth. The company reaffirmed full‑year 2026 net product revenue guidance of $1.0 billion to $1.04 billion, reflecting confidence based on first‑half performance.
Harmony also announced leadership changes. Chief Financial Officer Glenn Reicin stepped down effective July 16, 2026, under a Separation Agreement providing severance and a prorated target bonus consistent with his employment terms; the company stated his departure was not due to any disagreement on operations, policies or practices. Senior Vice President and Controller Stephen Mollichella was appointed Interim Principal Financial Officer, providing continuity in finance leadership. Harmony will report full Q2 2026 financial results and provide a business update on August 4, 2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to the exercise of options under a registered plan for 25,000 shares on 07/02/2026, to be settled for cash. The filing also lists multiple sales by Sandip Kapadia during June–July 2026, with recent transactions including 50,000 shares on 06/30/2026.
Sandip Kapadia reported transactions to sell up to 50,000 shares of Common Stock. The filing lists the method as an Exercise of Options Under a Registered Plan with cash settlement and names Morgan Stanley Smith Barney LLC as the broker.
The excerpt also discloses multiple sales by Sandip Kapadia in May and June 2026, with individual transactions and gross proceeds shown for each date.
HRMY affiliate files a notice of proposed sale under Form 144 for 45,594 shares. The filing states the disposition method as an exercise of options under a registered plan with cash proceeds, dated 06/26/2026. The excerpt also lists multiple sales by Sandip Kapadia totaling recent dispositions on 05/08/2026 through 06/24/2026.
Sandip Kapadia submitted a Form 144 notifying a proposed disposition of Common Stock under Rule 144. The filing lists Morgan Stanley Smith Barney LLC as the broker/agent and records recent dispositions: 45,481 shares (05/08/2026), 27,960 shares (06/09/2026), 7,064 shares (06/04/2026), and 2,101 shares (06/05/2026) with corresponding proceeds shown in the excerpt.
HRMY affiliate files Form 144 to report proposed and recent sales of Common Stock. The filing lists an exercise of options under a registered plan on 06/05/2026 for 27,960 shares and shows sales by Sandip Kapadia of 2,101 shares on 06/05/2026, 7,064 shares on 06/04/2026, and 45,481 shares on 05/08/2026 with cash proceeds reported for each transaction.